Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adeno...
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study
About this item
Full title
Author / Creator
Kindler, Hedy L, Dr , Ioka, Tatsuya, MD , Richel, Dirk J, MD , Bennouna, Jaafar, MD , Létourneau, Richard, MD , Okusaka, Takuji, MD , Funakoshi, Akihiro, MD , Furuse, Junji, MD , Park, Young Suk, MD , Ohkawa, Shinichi, MD , Springett, Gregory M, MD , Wasan, Harpreet S, MB , Trask, Peter C, PhD , Bycott, Paul, PhD , Ricart, Alejandro D, MD , Kim, Sinil, MD and Van Cutsem, Eric, MD
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Summary Background Axitinib is a potent, selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, and 3. A randomised phase 2 trial of gemcitabine with or without axitinib in advanced pancreatic cancer suggested increased overall survival in axitinib-treated patients. On the basis of these results, we aimed to assess the eff...
Alternative Titles
Full title
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study
Authors, Artists and Contributors
Author / Creator
Ioka, Tatsuya, MD
Richel, Dirk J, MD
Bennouna, Jaafar, MD
Létourneau, Richard, MD
Okusaka, Takuji, MD
Funakoshi, Akihiro, MD
Furuse, Junji, MD
Park, Young Suk, MD
Ohkawa, Shinichi, MD
Springett, Gregory M, MD
Wasan, Harpreet S, MB
Trask, Peter C, PhD
Bycott, Paul, PhD
Ricart, Alejandro D, MD
Kim, Sinil, MD
Van Cutsem, Eric, MD
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_855910813
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_855910813
Other Identifiers
ISSN
1470-2045
E-ISSN
1474-5488
DOI
10.1016/S1470-2045(11)70004-3
